Neuronal Exosomes Embroiled in Controversy
The L1CAM cell adhesion marker is a widely adopted marker of neuron-derived extracellular vesicles. Except it cannot be found in those teeny packets, claims a new study.
ALL NEWS
6562 RESULTS
Sort By:
- Most Recent
- Most Commented
Single Synapse Mass Spec Snags CD47 as Alzheimer’s Resilience Factor
Shooting synaptosomes through a mass spectrometer, scientists found that those with high CD47 and low ApoE were resilient in AD brain.
APP C-Terminal Fragments Stifle Calcium Flow from ER to Lysosomes
Amyloid precursor protein CTFs accumulate in lysosomes adjacent to endoplasmic reticulum. This disrupts calcium flow between the organelles.
Scratch Lanabecestat: This BACE Inhibitor Doesn’t Work in Symptomatic AD, Either
After veru- and atabecestat, now a third β-secretase inhibitor, by Eli Lilly and AstraZeneca, is being pulled from ongoing Phase 3 trials of symptomatic Alzheimer’s disease.
Protective APOE3 Variant Binds More Lipids, Self-Aggregates Less
The APOE3-Jacksonville variant generates a protein whose greater lipid-hauling capacity renders it less prone to self-aggregate. This boosted phospholipid trafficking and reduced the number of plaques and downstream damage.
San Diego: Treating Forgetfulness—Triple Transgenics Provoke
A mouse model that mimics both signature pathologies of Alzheimer disease develops a day-to-day forgetfulness at four months...
Fats, Aβ, Oxidative Stress: Feeding Forward and Backward, Killing Neurons?
Add a new strand to the growing web of relationships among production of the Aβ peptide, regulation of cholesterol and other lipids, oxidative stress, and the death of neurons in Alzheimer's. Researchers believe that Aβ drives an increase in the conversion of...
Lilly Halts IDENTITY Trials as Patients Worsen on Secretase Inhibitor
Eli Lilly and Company announced yesterday that it has halted its Semagacestat γ-secretase inhibitor program...
Law and Disorder—APPswe Patent Suits Raise Ruckus Again
The fight against Alzheimer disease rallies warriors of many sorts...
NIH Director Announces $100M Prevention Trial of Genentech Antibody
Francis Collins announced that $16 million of federal funds would go toward the first-ever therapeutic prevention trial in cognitively healthy people...
San Diego: Oligomers Live Up to Bad Reputation, Part 1
Over the past decade, researchers have shifted away from a literal interpretation of Alois Alzheimer’s groundbreaking discovery...
Breakthrough or False Hope? Etanercept Case Report Draws Scrutiny
Can an FDA-approved arthritis drug double as a therapy for Alzheimer disease?...
Target BACE: Better Than Ever?
In yesterday’s Neuron, researchers presented fresh in-vivo support for the amyloid hypothesis and bolster the status of the APP protease BACE as the current favorite target for AD therapy development...
Antibodies Stop Toxic Tau in Its Extracellular Tracks
Antibodies against extracellular tau block seeding, diminish brain pathology, and may improve cognition in a mouse model.
Mistakes Prompt Retraction of Controversial Paper, and Publication Ban
The Journal of Neuroscience retracted a paper that claimed Aβ does not accumulate inside neurons, and temporarily banished its senior authors.
Current Filters
No filters selected